Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 976 to 990 of 1835 results for carers

  1. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

    Highly specialised technologies guidance
    Published
    9 October 2019
    View recommendations

    Sections for HST11

  2. Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

    In development Reference number: GID-HTE10073 Expected publication date:  15 September 2026

    Health technology evaluations
    In development

  3. About NICE guidelines

    NICE guidelines are evidence-based recommendations for health and care in England and Wales.

  4. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (HTG353)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.

    HealthTech guidance
    Last updated
    19 December 2017
    View recommendations

    Sections for HTG353

  5. PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (HTG282)

    Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.

    HealthTech guidance
    Last updated
    19 July 2022
    View recommendations

    Sections for HTG282

  6. Zuranolone for treating postnatal depression [ID6431]

    In development Reference number: GID-TA11356 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Use of public open spaces by particular groups:- How effective and cost effective are environmental changes to increase physical activity through use of public open spaces (including blue, green and grey spaces) by the following groups:- black and minority ethnic groups- groups with low socioeconomic status- groups experiencing other forms of disadvantage, for example carers, people with severe mental health conditions?Are effects maintained over time?

    socioeconomic status- groups experiencing other forms of disadvantage, for example carers, people with severe mental health...

    Research recommendation
    Published
    15 November 2018

  8. Quality standard consultations

    quality improvements important to the service, patients, service users and carers achievable. Sometimes we ask specific questions, such...

  9. Quality standard consultations

    quality improvements important to the service, patients, service users and carers achievable. Sometimes we ask specific questions, such...

  10. How effective are the following interventions in the short, medium and long term, across various levels of risk and including diverse and marginalised groups: - advocacy - domestic abuse recovery programmes - perpetrator programmes - psychological or social interventions modified for domestic violence and abuse, including programmes for those who have suffered multiple forms of abuse and those who are still experiencing it - interventions for primary carers apart from mothers (for example, fathers, grandparents) - interventions for other family members?

    abuse and those who are still experiencing it - interventions for primary carers apart from mothers (for example, fathers, grandparents)...

    Research recommendation
    Published
    9 June 2015

  11. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.

    Highly specialised technologies guidance
    Published
    22 May 2019
    View recommendations

    Sections for HST9

  12. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence

  13. Venous thromboembolism in adults (QS201)

    This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 August 2021
    View quality statements

    Sections for QS201

  14. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  15. Indicator advisory committee (IAC)

    Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.